NASDAQ:ZEAL Zealand Pharma A/S (ZEAL) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free ZEAL Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$17.59▼$17.5950-Day Range$16.54▼$19.2052-Week Range$9.93▼$32.94VolumeN/AAverage Volume4,965 shsMarket Capitalization$818.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Zealand Pharma A/S alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Zealand Pharma A/S Stock (NASDAQ:ZEAL)Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.Read More Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> ZEAL Stock News HeadlinesApril 23, 2024 | tmcnet.comZealand Pharma Partners with Benchling to Advance R&D of Engineered Peptide MedicinesApril 19, 2024 | globenewswire.comCorrection to Company announcement – No. 23 / 2024April 26, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 19, 2024 | finance.yahoo.comZealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024April 19, 2024 | globenewswire.comTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsApril 19, 2024 | globenewswire.comZealand Pharma launches long-term incentive programs for Zealand's Board of Directors, Corporate Management and employees for 2024April 19, 2024 | msn.comMarkets with Madison: NZ medicinal cannabis company Cannasouth’s ex-chief executive Mark Lucas talks about what went wrongApril 19, 2024 | msn.comPharmac's perpetually stretched budgetApril 26, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 19, 2024 | msn.comNew Zealand Jobs: What is changing for new applicants of Accredited Employer Work VisaApril 19, 2024 | msn.comDrugs Like Ozempic And Mounjaro Could Treat Other Conditions—Here’s What Scientists Are Looking AtApril 12, 2024 | ft.comA ghost of Brexit past returns to haunt LabourApril 4, 2024 | morningstar.comU.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This YearMarch 31, 2024 | msn.comNew Zealand cancer trial: CAR T-cell therapy for lymphoma, leukaemia and myeloma is saving livesMarch 29, 2024 | msn.com'Oppenheimer' director Christopher Nolan will receive a knighthood in the UKMarch 28, 2024 | nz.finance.yahoo.comJessie J says she’s the opposite of a ‘beige mum’ as she shows off son’s playroomMarch 28, 2024 | msn.comNew Zealand Education: International student enrolments top 59,000 for the first eight months of 2023March 28, 2024 | msn.comOzempic maker Novo Nordisk gets more weight loss drug competition as a rival releases promising dataMarch 26, 2024 | globenewswire.comTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsMarch 26, 2024 | globenewswire.comZealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee WarrantsMarch 20, 2024 | globenewswire.comZealand Pharma's Annual General Meeting 2024March 19, 2024 | globenewswire.comTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsMarch 17, 2024 | businessinsider.comWeight loss drugs like Ozempic and Wegovy are fattening up Denmark's economy and helped it dodge a recession last yearMarch 15, 2024 | msn.comWhat is amycretin? The new weight-loss pill that’s ‘twice as effective’ as OzempicMarch 14, 2024 | yahoo.comFactbox-Madrigal's drug wins first US approval for fatty liver disease NASH as rivals circleMarch 13, 2024 | globenewswire.comNew Employee Elected Directors to the Board of Zealand Pharma A/SMarch 13, 2024 | msn.comWho benefits from direct-to-consumer pharmaceutical advertising?See More Headlines Receive ZEAL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ZEAL CUSIPN/A CIK1674988 Webwww.zealandpharma.com Phone(458) 877-3600Fax45-8877-3898Employees355Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-161,990,000.00 Net Margins-565.44% Pretax Margin-364.34% Return on Equity-111.04% Return on Assets-56.54% Debt Debt-to-Equity Ratio0.93 Current Ratio4.79 Quick Ratio4.78 Sales & Book Value Annual Sales$46.54 million Price / Sales17.59 Cash FlowN/A Price / Cash FlowN/A Book Value$3.38 per share Price / Book5.20Miscellaneous Outstanding Shares46,538,000Free Float45,514,000Market Cap$818.60 million OptionableNot Optionable Beta1.45 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Adam Sinding Steensberg M.D. (Age 48)Pres & CEO Comp: $680.16kMr. Ivan Mourits Moller (Age 50)Chief Operating Officer Lani Pollworth MorvanInvestor Relations & Communications OfficerMr. Mads KronborgHead of Investor Relations & CommunicationMr. Ravinder ChahilSr. VP & Gen. CounselMs. Christina Sonnenborg Bredal (Age 37)Sr. VP and Global Head of People & Organization Ms. Hanne Heidenheim Bak (Age 69)Sr. Project Director, R&D Operations Mang. and Employee Representative Director Dr. Jens Damsgaard Mikkelsen M.D.Head of Molecular PharmacologyDr. Danilo VergeHead of Global Medical AffairsDr. David M. Kendall M.D. (Age 60)Chief Medical Officer More ExecutivesKey CompetitorsARS PharmaceuticalsNASDAQ:SPRYEnliven TherapeuticsNASDAQ:ELVNTango TherapeuticsNASDAQ:TNGXArcutis BiotherapeuticsNASDAQ:ARQT89bioNASDAQ:ETNBView All Competitors ZEAL Stock Analysis - Frequently Asked Questions Should I buy or sell Zealand Pharma A/S stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZEAL shares. View ZEAL analyst ratings or view top-rated stocks. How were Zealand Pharma A/S's earnings last quarter? Zealand Pharma A/S (NASDAQ:ZEAL) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($4.61) EPS for the quarter, topping the consensus estimate of ($6.31) by $1.70. The company had revenue of $16.87 million for the quarter, compared to analysts' expectations of $12.21 million. Zealand Pharma A/S had a negative net margin of 565.44% and a negative trailing twelve-month return on equity of 111.04%. During the same quarter in the previous year, the company earned ($0.90) EPS. What other stocks do shareholders of Zealand Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zealand Pharma A/S investors own include AbbVie (ABBV), Galapagos (GLPG), Verizon Communications (VZ), Dynavax Technologies (DVAX), EyePoint Pharmaceuticals (EYPT), Progenics Pharmaceuticals (PGNX), Portola Pharmaceuticals (PTLA), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE). When did Zealand Pharma A/S IPO? Zealand Pharma A/S (ZEAL) raised $75 million in an IPO on Wednesday, August 9th 2017. The company issued 3,900,000 shares at $19.30 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers. This page (NASDAQ:ZEAL) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zealand Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
